Skip to main content
. 2012 May;166(2):557–568. doi: 10.1111/j.1476-5381.2011.01721.x

Figure 3.

Figure 3

(A) VT incidence in sham and failing hearts after infusion of erythromycin (⋆P < 0.05, significantly different from baseline) and additional infusion of verapamil (#P < 0.05, significantly different from erythromycin treatment). (B) Number of single VT episodes in sham and failing hearts after infusion of erythromycin (⋆P < 0.05, significantly different from baseline) and additional infusion of verapamil (#P < 0.05, significantly different from erythromycin treatment).